⬇️ Prefer to listen instead? ⬇️
- About 30% of epilepsy patients don’t respond to common antiepileptic drugs.
- Genetic changes in SCN1A and FGF12 have now been directly linked to focal epilepsy that doesn’t respond to drugs.
- Genome-wide association studies (GWAS) help find the genetic factors that affect how well epilepsy treatment works.
- Focal epilepsy treatment could be made better if we use pharmacogenomics, which tailors treatment to a person’s genes.
- Routine genetic testing may become important for epilepsy diagnosis and planning medication.
Epilepsy affects nearly 65 million people worldwide, and for about one-third of them, standard medications simply don’t work. This condition—known as drug-resistant epilepsy—is a difficult medical problem. But thanks to recent progress in genetic research, that problem is getting clearer. Scientists are now linking specific common genetic changes to the chance of medication resistance, particularly in focal epilepsy, the most common type in adults. This link between genes and treatment outcomes could soon change how neurologists diagnose and manage epilepsy right from the start.
Understanding Drug-Resistant Epilepsy
Drug-resistant epilepsy (DRE) is a serious condition where patients still have seizures even after trying two or more antiepileptic drugs (AEDs) that were right for them and used correctly. According to Kwan et al. (2010), about 30% of people with epilepsy are in this group, making it one of the big problems in modern neurology.
For those living with DRE, frequent seizures often make it hard to do things each day. Besides the immediate physical risks of seizures—like falls, injuries, and sudden death—patients often have long-term problems. These include problems with thinking, mental health issues, and big problems with social life. Not being able to drive, keep a job, or do normal social activities can lead to isolation and depression. Also, seizures are unpredictable. This causes ongoing fear and makes life unstable for both patients and caregivers.
DRE also costs a lot of money. Frequent hospital stays, expensive tests, and trying different medications for a long time greatly increase healthcare costs. Researchers and doctors are now working to change how epilepsy is managed. Instead of just giving drugs after seizures, they want care planned ahead of time for the person. This care would find people who likely won’t respond to drugs when they are first diagnosed.
What Is Focal Epilepsy and Why Is It Important?
Focal epilepsy, also called partial epilepsy, is when seizures start in a specific area or network in one half of the brain. These seizures are grouped into focal aware seizures, focal impaired awareness seizures, and focal to bilateral tonic-clonic seizures. This depends on how aware the person is and how the seizure spreads.
This type of epilepsy is most of the adult epilepsy cases and is very interesting to researchers because it often starts in one place. Unlike generalized epilepsy, which has electrical problems across the whole brain, focal epilepsy starts in one place. This means doctors can use more specific brain scans, consider surgery more often, and now, do genetic analysis.
Focal epilepsy is also a larger share of the people who have epilepsy that drugs don’t help. This makes it a main area of study for both doctors and geneticists. Understanding its genetic causes might mean better ways to treat focal epilepsy. These ways could include looking into surgery sooner, using drugs aimed at specific problems, and changing lifestyles.
Why Do Medications Fail? Possible Mechanisms
Even though there are many antiepileptic medications available, many patients don’t respond. This resistance is complicated, and doctors have suggested different reasons over time
Drug Transport Hypothesis
One main idea is that too many transporters that push drugs out at the blood-brain barrier stop AEDs from getting to the right levels in the brain and spinal cord. Proteins like P-glycoprotein (made from the MDR1 gene) can push drugs out of the brain. This makes them less effective no matter how much is given or how they are made.
Target Hypothesis
Another idea looks at where AEDs are supposed to work—mainly ion channels and neurotransmitter receptors. In patients whose drugs don’t work, changes in the genes that make these targets might change how they are built or how they work. This makes the drugs less effective, even though they are made to connect with them.
Genetic and Epigenetic Influence
Changes in genes and how genes are used can turn important genes “on” or “off.” This affects how active the brain is and how well medication works. Things like what a person is exposed to in the environment, diet, infections, and other life events can make things more complicated. They can change how a person’s genes work, making treatment even harder.
Genetic Variants and Medication Resistance
Most recently, strong information shows the part played by common genetic changes in figuring out if a patient is likely to have medication not work. Finding that certain single nucleotide polymorphisms (SNPs) in specific genes are linked to treatment resistance helps explain on a molecular level why some patients don’t respond. This is starting a new time in epilepsy care.
New Research Connects Common Genetic Variants to Drug Resistance
An important new genome-wide association study (GWAS) published by Popovic et al. in 2024 looked at over 3,000 people with focal epilepsy that drugs didn’t help. They compared their DNA to more than 3,700 people without this issue. This big study found clear links with two specific genes
FGF12 – Fibroblast Growth Factor 12
Changes in FGF12 were found much more often in patients whose drugs didn’t work. FGF12 is very important for controlling voltage-gated sodium channels. These proteins are needed to start and spread electrical signals in nerve cells. Problems in this control can make nerve cells too active. This contributes to having seizures and not responding well to AEDs.
SCN1A – Sodium Voltage-Gated Channel Alpha Subunit 1
SCN1A has long been known for its role in seizure syndromes like Dravet syndrome. Now, it is also known to affect treatment resistance in focal epilepsy. This gene provides instructions for a main part of the voltage-gated sodium channel. Changes in this gene can impact how well certain medications work, especially those that block sodium channels.
These findings show that resistance may not happen just because someone takes drugs for a long time. Instead, it may be built into their biology from birth in some patients.
The Science Behind the Study
The study by Popovic et al. used the GWAS method to look at genetic differences between those who responded to drugs and those who didn’t. GWAS looks through DNA for SNPs. These are small changes in the DNA sequence that might play a part in diseases.
Everyone has millions of these changes. So, studies need to look at many people to tell the difference between real links and random noise. Finding FGF12 and SCN1A this way—and confirming this in other groups—not only shows they are important. It also makes doctors more sure about using genetic results when deciding on care.
These types of studies are also helping to create polygenic risk scores. With these scores, the total effect of thousands of SNPs helps predict a person’s risk for conditions like epilepsy or not responding to drugs.
What Does This Mean for Diagnosis?
The main way doctors diagnose epilepsy currently uses brain scans, patient history, and EEG data. However, adding genetics into this is already happening. This is expected to greatly change early diagnosis and treatment planning.
If specific genetic changes are known to make a patient more likely to have drug resistance, genetic testing could become a standard part of the first check-up. Doctors might then try different things from the start, such as
- Choosing different types of AEDs
- Focusing on early checks for surgery
- Adding other treatments earlier
- Getting patients ready for a different path for managing their epilepsy
Early genetic testing could quickly cut down the time patients spend on treatments that don’t work. This cuts down on how often they have seizures, side effects that affect thinking, and feeling frustrated.
Rethinking Treatment Strategies Through Genetics
Personalized medicine is rising. This is when treatments are made to fit each person’s differences. It has already changed areas like cancer treatment and is now having an effect in neurology.
For focal epilepsy treatment, pharmacogenomics looks very promising. Genetic testing could find markers in a patient’s genes. These markers could tell if a drug will help or hurt. For example
- People with SCN1A mutations might not do well with sodium channel blockers. Instead, they need other treatments.
- Some changes in FGF12 might show a need for new treatments. These treatments could fix faulty nerve cell control instead of just stopping seizure signs.
Furthermore, ongoing clinical trials may start grouping people based on their genes. This makes sure drugs are tested in people who have certain genes. This change would make new treatments more reliable and safer.
Could Genetic Testing Become Routine in Epilepsy Clinics?
The idea of routine genetic testing is good, but making it happen has several problems
Financial Barriers
Genetic testing, especially tests looking at all genes, is still expensive. While prices have gone down, insurance doesn’t always pay for it. This often makes it hard for patients without a lot of money to get it.
Healthcare Infrastructure
Genetic testing is only useful if the results are understood right. Many neurology clinics currently don’t have genetic doctors or counselors. This leaves holes in diagnosis, education, and putting treatment into action. More training across different hospitals and clinics is needed to make sure regular doctors understand genetics.
Psychological and Ethical Considerations
Telling a patient or family that genetic markers show that treatment likely won’t work well can be upsetting. There must be good mental health and counseling help available to support people dealing with complicated information about what might happen.
Despite these problems, testing just a few genes that have a big effect, like SCN1A and FGF12, could be a first step to doing it more widely.
Implications for Drug Development
For the drug industry, this new understanding of genetics provides a clear path for making the next types of epilepsy medications. Aiming at molecular pathways linked to resistance—like those affected by FGF12 or SCN1A—might lead to drugs that work when older drugs don’t.
Moreover, drug trials might be changed to include only people with or without certain genetic changes. This cuts down differences and makes results clearer about how well drugs work. This fits with the growing area of treatment plans for specific gene types.
Looking at multiple genes might also help find groups of patients who are not well identified by current diagnosis methods. This gives them hope for treatment just for them.
Real-World Application: A Look Ahead
Genetics could take the guesswork out of epilepsy management. Imagine a time when a doctor can look at a patient’s genetic report before prescribing drugs. This could mean
- Seizures controlled faster
- Fewer treatments that don’t work
- Less guessing about which drug to try
- Fewer side effects
This change would not only help patients. It would also cut down on costs for healthcare systems by cutting down on expensive hospital stays and emergency visits.
Of course, going from finding things out to using them with patients will take time. It will need researchers, doctors, insurers, and policymakers all working together.
Intersection with Mental Health and Daily Functioning
Drug-resistant epilepsy often causes problems not just for the brain, but for how a person feels. Patients often feel anxious or depressed and are treated unfairly. This makes the main health problem worse.
Finding out that a patient’s epilepsy is more likely to not respond to drugs because of their genes might feel heavy emotionally. That’s why it’s very important to use a way of treating that looks at biology, psychology, and social factors. This brings together
- Neurologists to manage the medical side
- Psychologists and psychiatrists for emotional support
- Social workers to help people connect with their community
Looking after the whole person makes sure that knowing about genetic risk doesn’t just feel like another problem. Instead, it is something that helps build strength and support systems made just for them.
Bridging Research and Public Understanding
For this science that can make a big change to be used in the real world, people outside the lab need to know about it. Organizations like The Neuro Times aim to connect new discoveries with what people understand.
Reaching out to teach people, summaries in simple words, and tools to help make choices can help patients understand new genetic information. These can also help them speak up for themselves within a quickly changing healthcare system.
As we learn more about how genetic changes affect epilepsy that drugs don’t help and how to treat focal epilepsy, teaching many people will help. It will lead to better conversations, getting help sooner, and more hope for those who often feel stuck because of their diagnosis.
If you’re interested in staying ahead of developments in epilepsy genetics and treatment, be sure to check out the latest at The Neuro Times.
Citations
- Kwan, P., Arzimanoglou, A., Berg, A. T., et al. (2010). Definition of drug-resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia, 51(6), 1069–1077. https://doi.org/10.1111/j.1528-1167.2009.02397.x
